This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Jul 7;370(9581):3-5.

doi: 10.1016/S0140-6736(07)61022-8.

No patient left behind--better treatments for resistant HIV infection

Bernard Hirschel¹, Thomas Perneger

Affiliations

PMID: 17617250
DOI: 10.1016/S0140-6736(07)61022-8

Comment

No patient left behind--better treatments for resistant HIV infection

Bernard Hirschel et al. Lancet. 2007.

. 2007 Jul 7;370(9581):3-5.

doi: 10.1016/S0140-6736(07)61022-8.

Authors

Bernard Hirschel¹, Thomas Perneger

Affiliation

¹ Division of Infectious Diseases, Geneva University Hospital, Geneva 1211, Switzerland. Bernard.hirschel@hcuge.ch

PMID: 17617250
DOI: 10.1016/S0140-6736(07)61022-8

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group. Madruga JV, et al. Lancet. 2007 Jul 7;370(9581):29-38. doi: 10.1016/S0140-6736(07)61047-2. Lancet. 2007. PMID: 17617270 Clinical Trial.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group. Lazzarin A, et al. Lancet. 2007 Jul 7;370(9581):39-48. doi: 10.1016/S0140-6736(07)61048-4. Lancet. 2007. PMID: 17617271 Clinical Trial.
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzman S; TITAN study group. Madruga JV, et al. Lancet. 2007 Jul 7;370(9581):49-58. doi: 10.1016/S0140-6736(07)61049-6. Lancet. 2007. PMID: 17617272 Clinical Trial.

Similar articles

Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW, Montaner JS. Hull MW, et al. Expert Opin Pharmacother. 2010 Jun;11(8):1433-7. doi: 10.1517/14656561003724754. Expert Opin Pharmacother. 2010. PMID: 20367279
New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar M, Cartledge JD. Lascar M, et al. J HIV Ther. 2008 Jun;13(2):40-4. J HIV Ther. 2008. PMID: 18953273 Review. No abstract available.
Drug interactions. Interactions with TMC114 and TMC125.
[No authors listed] [No authors listed] TreatmentUpdate. 2006 Jun-Jul;18(3):8-9. TreatmentUpdate. 2006. PMID: 17211920 No abstract available.
48-week study results show DRV's staying power.
Bernard EJ. Bernard EJ. IAPAC Mon. 2007 Jan;13(1):10-1. IAPAC Mon. 2007. PMID: 17523243 No abstract available.
Darunavir: an effective protease inhibitor for HIV-infected patients.
Phung BC, Yeni P. Phung BC, et al. Expert Rev Anti Infect Ther. 2011 Jun;9(6):631-43. doi: 10.1586/eri.11.48. Expert Rev Anti Infect Ther. 2011. PMID: 21692667 Review.

See all similar articles

Cited by

Profile of darunavir in the management of treatment-experienced HIV patients.
Wolfe C, Hicks C. Wolfe C, et al. HIV AIDS (Auckl). 2009;1:13-21. doi: 10.2147/hiv.s4842. Epub 2009 Sep 29. HIV AIDS (Auckl). 2009. PMID: 22096376 Free PMC article.
Combating Non-nucleoside Reverse Transcriptase Inhibitor Resistance with a Focus On Etravirine (Intelence) for HIV-1 Infection.
Eraikhuemen N, Thornton AM, Branch E, Huynh ST, Farley C. Eraikhuemen N, et al. P T. 2008 Aug;33(8):445-91. P T. 2008. PMID: 19750175 Free PMC article. No abstract available.
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.
van 't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, van Velsen F, Baert L. van 't Klooster G, et al. Antimicrob Agents Chemother. 2010 May;54(5):2042-50. doi: 10.1128/AAC.01529-09. Epub 2010 Feb 16. Antimicrob Agents Chemother. 2010. PMID: 20160045 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information